<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373930</url>
  </required_header>
  <id_info>
    <org_study_id>201674</org_study_id>
    <nct_id>NCT02373930</nct_id>
  </id_info>
  <brief_title>Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects</brief_title>
  <official_title>A Phase I, 2-part Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Fasted and Fed Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration&#xD;
      of a combination of antiretroviral drugs to reduce the patient's HIV levels. Dolutegravir&#xD;
      (DTG), a HIV-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1&#xD;
      reverse transcriptase inhibitor (NNRTI), are approved for the treatment of HIV infection.&#xD;
      This study is aimed to evaluate the relative bioavailability and food effect of single doses&#xD;
      of several experimental fixed dose combination (FDC) tablets of Dolutegravir 50 milligrams&#xD;
      (mg) and Rilpivirine 25 mg (DTG/RPV 50 mg/25 mg) relative to co-administration of a single&#xD;
      dose of the reference single entity products (DTG 50 mg and RPV 25 mg) in healthy adult&#xD;
      subjects. This is a 2-part study. Part 1 will be conducted as a randomized, open label,&#xD;
      3-way, crossover design in 24 subjects. Part 1 will evaluate the relative bioavailability of&#xD;
      up to 4 test formulations relative to the reference single entity products administered in&#xD;
      fed state. Part 2 will be conducted as a randomized, open-label, 3-way crossover design in 3&#xD;
      distinct cohorts each with 12 subjects. Part 2 will evaluate the relative bioavailability of&#xD;
      up to 3 most promising FDC formulation selected from Part 1 (DTG/RPV FDC-1, DTG/RPV FDC-2,&#xD;
      DTG/RPV FDC-3) administered in fasted and fed state. Subjects will also receive the reference&#xD;
      treatment from Part 1 co-administered under fasted conditions. This study will consist of a&#xD;
      screening visit, three treatment periods each with a single dose of study drug separated by a&#xD;
      washout of at least 9 days and a follow-up visit. The total duration of participation of a&#xD;
      subject in this study will be approximately 10 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetic (PK) parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)</measure>
    <time_frame>Part 1: Pre-dose and 0.25 hours (h), 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-Infinity]), maximum observed concentration (Cmax) and apparent oral clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)</measure>
    <time_frame>Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include AUC (0-Infinity), Cmax and CL/F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)</measure>
    <time_frame>Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include AUC (0-Infinity), Cmax and CL/F</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fed state (Part 1)</measure>
    <time_frame>Part 1: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include area under the curve from time of dose administration to time of last quantifiable post-dose sample (AUC[0-t]), observed concentration at 24 h post-dose (C24), terminal elimination phase half-life (t1/2), lag time for absorption (tlag) and time to maximum observed concentration (tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters of a single dose of DTG and RPV administered together in a FDC tablet compared to co-administration of the single-entity DTG and RPV products in fasted state (Part 2)</measure>
    <time_frame>Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include AUC (0-t), C24, t1/2, tlag and tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters of DTG and RPV to evaluate the effect of food on the bioavailability of selected FDC formulation(s) of DTG and RPV (Part 2)</measure>
    <time_frame>Part 2: Pre-dose and 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 9 h, 12 h, 16 h, 24 h, 48 h, 72 h, 120 h, and 168 hours post-dose in each treatment period.</time_frame>
    <description>PK parameters will include AUC (0-t), C24, t1/2, tlag and tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in vital signs</measure>
    <time_frame>Part 1 and 2: Baseline (Day 1) and up to Day 35</time_frame>
    <description>Vital signs will include systolic and diastolic blood pressure and pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Part 1 and 2: Up to Day 35</time_frame>
    <description>AEs and serious adverse events (SAEs) will be collected from the start of study treatment until the follow-up contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of clinical laboratory assessments</measure>
    <time_frame>Part 1 and 2: Up to Day 35</time_frame>
    <description>Clinical laboratory tests will include hematology, clinical chemistry, urinalysis parameters</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1- Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication. All treatments will be administered in fed state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of &gt;=9 days between doses of study medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG 50 mg</intervention_name>
    <description>Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 3</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 4</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 5</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPV 25 mg</intervention_name>
    <description>Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 3</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 4</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 5</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/RPV 50 mg/25 mg: Product Code AS</intervention_name>
    <description>DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/RPV 50 mg/25 mg: Product Code AM</intervention_name>
    <description>DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 4</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/RPV 50 mg/25 mg: Product Code AQ</intervention_name>
    <description>DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 2</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 4</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/RPV 50 mg/25 mg: Product Code AK</intervention_name>
    <description>DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally</description>
    <arm_group_label>Part 1 Cohort 1- Sequence 3</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 5</arm_group_label>
    <arm_group_label>Part 1 Cohort 1- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG/RPV 50 mg/25 mg: Product Code AR</intervention_name>
    <description>DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally</description>
    <arm_group_label>Part 2 Cohort 2- Sequence 1</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 2</arm_group_label>
    <arm_group_label>Part 2 Cohort 2- Sequence 3</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 4</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 5</arm_group_label>
    <arm_group_label>Part 2 Cohort 3- Sequence 6</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 7</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 8</arm_group_label>
    <arm_group_label>Part 2 Cohort 4- Sequence 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 and 65 years of age inclusive, at the time of signing the informed consent.&#xD;
&#xD;
          -  Healthy as determined by the investigator or medically qualified designee based on a&#xD;
             medical evaluation including medical history, physical examination, laboratory tests&#xD;
             and cardiac evaluation (history, electrocardiogram [ECG]).&#xD;
&#xD;
          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not&#xD;
             specifically listed in the inclusion or exclusion criteria, outside the reference&#xD;
             range for the population being studied may be included only if the investigator in&#xD;
             consultation with the medical monitor if required agree and document that the finding&#xD;
             is unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures.&#xD;
&#xD;
          -  Body weight &gt;=50 kilograms (kg) (110 pounds [lbs]) for men and &gt;=45 kg (99 lbs) for&#xD;
             women and body mass index (BMI) within the range 18.5-31.0 kg/square meter (m^2)&#xD;
             (inclusive).&#xD;
&#xD;
          -  Male or Female- Female: Female subject of non-reproductive potential : is eligible to&#xD;
             participate if she is not pregnant (as confirmed by a negative serum or urine human&#xD;
             chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following&#xD;
             conditions applies: Pre-menopausal females with one of the following: documented tubal&#xD;
             ligation, documented hysteroscopic tubal occlusion procedure with follow-up&#xD;
             confirmation of bilateral tubal occlusion, hysterectomy, documented bilateral&#xD;
             oophorectomy.&#xD;
&#xD;
        Postmenopausal defined as 12 months of spontaneous amenorrhea; in questionable cases a&#xD;
        blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels&#xD;
        consistent with menopause (refer to laboratory reference ranges for confirmatory levels).&#xD;
        Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of&#xD;
        post-menopausal status prior to study enrolment.&#xD;
&#xD;
        Reproductive potential and agrees to follow one of the options listed below in the&#xD;
        GlaxoSmithKline (GSK) modified list of highly effective methods for avoiding pregnancy in&#xD;
        females of reproductive potential (FRP) requirements from 30 days prior to the first dose&#xD;
        of study medication and until at least five terminal half-lives (10 days) after the last&#xD;
        dose of study medication and completion of the follow-up visit.&#xD;
&#xD;
        GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of&#xD;
        Reproductive Potential (FRP)&#xD;
&#xD;
        This list does not apply to FRP with same sex partners, when this is their preferred and&#xD;
        usual lifestyle or for subjects who are and will continue to be abstinent from&#xD;
        penile-vaginal intercourse on a long term and persistent basis.&#xD;
&#xD;
          -  Intrauterine device that meets the standard operating procedure (SOP) effectiveness&#xD;
             criteria including a &lt;1% rate of failure per year, as stated in the product label.&#xD;
&#xD;
          -  Male partner sterilization with documentation of azoospermia prior to the female&#xD;
             subject's entry into the study, and this male is the sole partner for that subject.&#xD;
&#xD;
          -  Male condom combined with a vaginal spermicide (foam, gel, film, cream, or&#xD;
             suppository).&#xD;
&#xD;
        These allowed methods of contraception are only effective when used consistently, correctly&#xD;
        and in accordance with the product label. The investigator is responsible for ensuring that&#xD;
        subjects understand how to properly use these methods of contraception.&#xD;
&#xD;
        Male:&#xD;
&#xD;
          -  Male subjects with female partners of child bearing potential must comply with the&#xD;
             following contraception requirements from the time of first dose of study medication&#xD;
             until [at least five half-lives of study medication OR for a cycle of spermatogenesis&#xD;
             following five terminal half-lives] after the last dose of study medication.&#xD;
&#xD;
               1. Vasectomy with documentation of azoospermia.&#xD;
&#xD;
               2. Male condom plus partner use of one of the contraceptive options below:&#xD;
&#xD;
          -  Contraceptive subdermal implant that meets the SOP effectiveness criteria including a&#xD;
             &lt;1% rate of failure per year, as stated in the product label.&#xD;
&#xD;
          -  Intrauterine device or intrauterine system that meets the SOP effectiveness criteria&#xD;
             including a &lt;1% rate of failure per year, as stated in the product label.&#xD;
&#xD;
          -  Oral Contraceptive, either combined or progestrogen alone.&#xD;
&#xD;
          -  Injectable progestrogen.&#xD;
&#xD;
          -  Contraceptive vaginal ring.&#xD;
&#xD;
          -  Percutaneous contraceptive patches.&#xD;
&#xD;
        These allowed methods of contraception are only effective when used consistently, correctly&#xD;
        and in accordance with the product label. The investigator is responsible for ensuring that&#xD;
        subjects understand how to properly use these methods of contraception.&#xD;
&#xD;
          -  Capable of giving signed informed consent as described in protocol which includes&#xD;
             compliance with the requirements and restrictions listed in the consent form and in&#xD;
             this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and bilirubin &gt;1.5x upper limit of normal (ULN)&#xD;
             (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin &lt;35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GSK medical monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: An&#xD;
             average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. One drink is&#xD;
             equivalent to 12 grams (g) of alcohol: 12 ounces (360 milliliter [mL]) of beer, 5&#xD;
             ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or medical&#xD;
             monitor, contraindicates their participation.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test&#xD;
             result at screening or within 3 months prior to first dose of study treatment.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood product in&#xD;
             excess of 500 mL within 56 days.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility&#xD;
             determination):&#xD;
&#xD;
        Heart Rate for males: &lt;45 and &gt;100 beats per minute (bpm), females: &lt;50 and &gt;100 bpm PR&#xD;
        Interval for males: &lt;120 and &gt;220 milliseconds (msec) QRS Interval for males: &lt;70 and &gt;120&#xD;
        msec QT duration corrected for heart rate (QTc) interval (Fridericia's) for males: &gt;450&#xD;
        msec Note: A heart rate from 100 to 110 bpm can be rechecked by ECG or vitals within 30&#xD;
        minutes to verify eligibility.&#xD;
&#xD;
        Evidence of previous myocardial infarction (does not include ST segment changes associated&#xD;
        with repolarization).&#xD;
&#xD;
        Any conduction abnormality (including but not specific to left or right complete bundle&#xD;
        branch block, atrioventricular block (AV block) (2nd degree or higher), Wolf Parkinson&#xD;
        White [WPW] syndrome).&#xD;
&#xD;
        Sinus Pauses &gt;3 seconds. Any significant arrhythmia which, in the opinion of the principal&#xD;
        investigator OR GSK medical monitor, will interfere with the safety for the individual&#xD;
        subject.&#xD;
&#xD;
        Non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular ectopic&#xD;
        beats).&#xD;
&#xD;
          -  Employment with Janssen and GSK or with the Investigator or study site, with direct&#xD;
             involvement in the proposed study or other studies under the direction of that&#xD;
             Investigator or study site, as well as family members of the employees or the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dolutegravir</keyword>
  <keyword>safety</keyword>
  <keyword>Rilpivirine</keyword>
  <keyword>fixed dose combination</keyword>
  <keyword>relative bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

